B+
Bull case
15%
Probability
Target price
$8.50
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
UNCY
Unicycive TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexB
Base case
35%
Probability
Target price
$4.50
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
Most likely
B-
Bear case
50%
Probability
Target price
$2.75
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-04
Recent news sentiment (30D)
-0.8
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+37.3
Score
AI commentary
News tone is strongly negative following the June 30 CRL and associated share-price reaction. The primary-source message is mixed rather than uniformly bearish: FDA did not identify clinical efficacy or safety concerns, but the repeat manufacturing issue removes the prior near-term approval catalyst. Social, options, short-interest, employee-review, and analyst-revision data are unavailable, so confidence remains low and the appropriate posture is monitoring rather than an aggressive directional thesis.
RankAlpha Sentiment Codex - 2026-08-04
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-06-30eventFDA Complete Response Letter resets OLC approval timelineHigh impact
The June 30 FDA CRL cited the same third-party manufacturing deficiencies as the prior CRL; the company said FDA raised no clinical efficacy or safety concerns and requested no additional data [#IR-2026-06-30]. The event is already reflected in sharply negative headlines.
2027-08-04catalystManufacturing remediation, FDA inspection, and NDA resubmissionHigh impact
Upside depends on resolving the vendor deficiencies, completing an FDA inspection, and resubmitting OLC. Management described discussions with FDA as ongoing and expressed optimism about an expeditious resubmission, but provided no firm timing [#IR-2026-06-30].
2027-08-04catalystCash runway through the remediation periodHigh impact
The company reported approximately $61.4 million of cash as of June 30, 2026 [#SEC-8K-2026-07-02]. Earlier company reporting indicated resources into 2027, but ongoing losses, commercialization delays, and the stated need for future capital leave dilution risk unresolved [#SEC-8K-2026-05-12].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-04 • Updated nightlySource: Internal modelMethodology